Literature DB >> 12177164

Macrophage-specific expression of class A scavenger receptors in LDL receptor(-/-) mice decreases atherosclerosis and changes spleen morphology.

Stewart C Whitman1, Debra L Rateri, Stephen J Szilvassy, Joseph A Cornicelli, Alan Daugherty.   

Abstract

Class A scavenger receptors (SR-A) have been implicated in the atherogenic process, although there have been conflicting reports as to their specific effect on the development of lesions. In part, this discord may arise because of the variable contribution of SR-A in the several cell types known to express this protein. To determine the effects of macrophage-specific SR-A expression in the atherogenic process, transgenic mice were created using the chicken lysozyme (lyso) promoter to drive expression of bovine SR-A (bSR-A). To express this gene in an atherosclerosis-susceptible strain, bone marrow cells from transgenic and non-transgenic littermates were used to repopulate lethally-irradiated female LDL receptor (LDLr)(-/-) mice. Following hematopoietic engraftment, mice were placed on a diet enriched in saturated fat and cholesterol. After 8 weeks, there was a modest, but statistically significant reduction in serum total cholesterol in LDLr(-/-) mice repopulated with lyso-bSR-A transgenic cells, due to decreased LDL-cholesterol. The extent of atherosclerosis was reduced in both cross-sectional analysis of the aortic root and en face analysis of the intimal surface of the aortic arch. In addition to changes in atherosclerosis, lyso-bSR-A repopulated LDLr(-/-) mice had a marked increase (3.6x) in spleen weights and a disruption of spleen white pulp formation. Therefore, macrophage-specific overexpression of SR-A resulted in reduced atherosclerosis in two vascular beds, reduced serum cholesterol concentrations, and changed the morphology of the spleen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12177164

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  15 in total

1.  Macrophage-specific overexpression of interleukin-5 attenuates atherosclerosis in LDL receptor-deficient mice.

Authors:  W Zhao; T Lei; H Li; D Sun; X Mo; Z Wang; K Zhang; H Ou
Journal:  Gene Ther       Date:  2015-04-14       Impact factor: 5.250

2.  Targeting Innate Immunity for CV Benefit.

Authors:  Kathryn J Moore; Mason W Freeman
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 3.  Class A1 scavenger receptors in cardiovascular diseases.

Authors:  Jingjing Ben; Xudong Zhu; Hanwen Zhang; Qi Chen
Journal:  Br J Pharmacol       Date:  2015-03-27       Impact factor: 8.739

4.  Evaluation of macrophage-specific promoters using lentiviral delivery in mice.

Authors:  M C Levin; U Lidberg; P Jirholt; M Adiels; A Wramstedt; K Gustafsson; D R Greaves; S Li; S Fazio; M F Linton; S-O Olofsson; J Borén; I Gjertsson
Journal:  Gene Ther       Date:  2011-12-01       Impact factor: 5.250

Review 5.  From proliferation to proliferation: monocyte lineage comes full circle.

Authors:  Filip K Swirski; Ingo Hilgendorf; Clinton S Robbins
Journal:  Semin Immunopathol       Date:  2014-01-17       Impact factor: 9.623

6.  Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice.

Authors:  Kathryn J Moore; Vidya V Kunjathoor; Stephanie L Koehn; Jennifer J Manning; Anita A Tseng; Jessica M Silver; Mary McKee; Mason W Freeman
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

7.  Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages.

Authors:  Xinbing Han; Shiro Kitamoto; Qingyu Lian; William A Boisvert
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

8.  IL-19 Halts Progression of Atherosclerotic Plaque, Polarizes, and Increases Cholesterol Uptake and Efflux in Macrophages.

Authors:  Khatuna Gabunia; Stephen Ellison; Sheri Kelemen; Farah Kako; William D Cornwell; Thomas J Rogers; Prasun K Datta; Mireille Ouimet; Kathryn J Moore; Michael V Autieri
Journal:  Am J Pathol       Date:  2016-03-04       Impact factor: 4.307

9.  CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein.

Authors:  Paul Gutwein; Mohamed Sadek Abdel-Bakky; Anja Schramme; Kai Doberstein; Nicole Kämpfer-Kolb; Kerstin Amann; Ingeborg A Hauser; Nicholas Obermüller; Christine Bartel; Abdel-Aziz H Abdel-Aziz; El Sayed M El Sayed; Josef Pfeilschifter
Journal:  Am J Pathol       Date:  2009-05-12       Impact factor: 4.307

10.  Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques.

Authors:  Daniel R Lewis; Latrisha K Petersen; Adam W York; Sonali Ahuja; Hoonbyung Chae; Laurie B Joseph; Saum Rahimi; Kathryn E Uhrich; Paul B Haser; Prabhas V Moghe
Journal:  Cardiovasc Res       Date:  2015-10-14       Impact factor: 13.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.